| # | Title | Journal | Year | Citations |
|---|
| 1 | COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus | Leukemia | 2020 | 198 |
| 2 | Clinical manifestation of myeloperoxidase deficiency | Journal of Molecular Medicine | 1998 | 161 |
| 3 | Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes | Leukemia | 2015 | 122 |
| 4 | Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion | Blood | 2006 | 109 |
| 5 | Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding | Hematological Oncology | 2018 | 55 |
| 6 | Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes | Leukemia | 2008 | 45 |
| 7 | INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia | Blood Advances | 2022 | 33 |
| 8 | A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome | Leukemia | 2007 | 30 |
| 9 | Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs | Blood | 2021 | 30 |
| 10 | Circulating endothelial cells in patients with chronic lymphocytic leukemia | Cancer | 2010 | 29 |
| 11 | Cytogenetic aspects of B-cell chronic lymphocytic leukemia: Their correlation with clinical stage and different polyclonal mitogens | Cancer Genetics and Cytogenetics | 1987 | 27 |
| 12 | Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone | Hematological Oncology | 2013 | 25 |
| 13 | Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis | Frontiers in Neurology | 2018 | 23 |
| 14 | Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model | Oncogene | 2017 | 22 |
| 15 | Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high‐risk subgroups | Cancer Medicine | 2014 | 21 |
| 16 | Assessment of distribution of CD34 epitope classes in fresh and cryopreserved peripheral blood progenitor cells and acute myeloid leukemic blasts | Haematologica | 1999 | 19 |
| 17 | Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study | Leukemia | 2021 | 17 |
| 18 | TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia | Frontiers in Oncology | 2021 | 17 |
| 19 | Thrombosis of the cerebral veins and sinuses in acute promyelocytic leukemia after all-trans retinoic acid treatment: a case report | Blood Coagulation and Fibrinolysis | 2008 | 13 |
| 20 | Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group | American Journal of Hematology | 2020 | 12 |
| 21 | Eosinophil peroxidase deficiency detected by the Technicon H 1 system | Blut | 1988 | 10 |
| 22 | Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study | American Journal of Hematology | 2021 | 10 |
| 23 | Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients | Oncotarget | 2014 | 10 |
| 24 | Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report | Hematological Oncology | 2021 | 9 |
| 25 | Predictive value of hematological and phenotypical parameters on postchemotherapy leukocyte recovery | Cytometry Part B - Clinical Cytometry | 2009 | 8 |
| 26 | Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group | Hematological Oncology | 2021 | 8 |
| 27 | TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases | American Journal of Hematology | 2021 | 8 |
| 28 | Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab | Blood Cancer Journal | 2020 | 7 |
| 29 | COVID-19 and Chronic Lymphocytic Leukemia | Cancer Journal (Sudbury, Mass ) | 2021 | 7 |
| 30 | Multiple myeloma with Auer-rod-like inclusions | Haematologica | 1999 | 7 |
| 31 | Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases | European Journal of Haematology | 2021 | 5 |
| 32 | Treatment with ibrutinib does not induce a <I>TP53</I> clonal evolution in chronic lymphocytic leukemia | Haematologica | 2022 | 4 |
| 33 | Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials | American Journal of Hematology | 2021 | 3 |
| 34 | Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia | Hematological Oncology | 2023 | 3 |
| 35 | Further cytogenetic evidence for a multistep pathogenesis of Ph-positive chronic myelogenous leukemia | Cancer Genetics and Cytogenetics | 1985 | 2 |
| 36 | Erythrocytes | Cancer Genetics and Cytogenetics | 1998 | 2 |
| 37 | The role of rHuEpo in low-risk myelodysplastic syndrome patients | Leukemia and Lymphoma | 2005 | 2 |
| 38 | Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints | Cancer Journal (Sudbury, Mass ) | 2021 | 2 |
| 39 | The Monocytic Component in Myelodysplastic Syndromes | Cancer Treatment and Research | 2001 | 2 |
| 40 | Automated flow cytochemistry in measuring chronic lymphocytic leukemia- and healthy adult-cells | Blut | 1986 | 1 |
| 41 | Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL | Blood | 2021 | 1 |
| 42 | S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA | HemaSphere | 0 | 1 |
| 43 | P596: CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE | HemaSphere | 0 | 1 |
| 44 | Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real‐World” study | American Journal of Hematology | 2023 | 1 |
| 45 | Cytogenetically distinct leukemic cell lines displaying in vitro specific proliferative and differentiation capacities may account for early disease relapse in the blast phase of CML | Cancer Genetics and Cytogenetics | 1985 | 0 |
| 46 | Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study | Blood | 2021 | 0 |
